Explore
Search ClinicalTrials.gov
Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.
Results for “United Kingdom”
Sponsor: Boehringer Ingelheim
Healthy
United Kingdom
- Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus NephritisActive Not Recruiting
Sponsor: Novartis Pharmaceuticals
Lupus Nephritis
United States, Argentina, Brazil, Canada, Chile +22 more
Sponsor: Encoded Therapeutics
Dravet Syndrome
United States, Australia, United Kingdom
Sponsor: Novartis Pharmaceuticals
Hidradenitis Suppurativa
United States, Argentina, Australia, Austria, Belgium +33 more
- An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus ErythematosusEnrolling By Invitation
Sponsor: Biogen
Systemic Lupus Erythematosus (SLE)
United States, Argentina, Belgium, Brazil, Bulgaria +23 more
Sponsor: Eli Lilly and Company
Alcohol Use Disorder
United States, Belgium, China, Germany, Japan +3 more
Sponsor: Eli Lilly and Company
Opioid Use Disorder
United States, Canada, Puerto Rico, United Kingdom
Sponsor: Boehringer Ingelheim
Metabolic Dysfunction Associated Steatohepatitis (MASH) · Liver Fibrosis
United States, Argentina, Australia, Austria, Belgium +31 more
Sponsor: Merck Sharp & Dohme LLC
Heart Failure · Left Ventricular Systolic Dysfunction
United States, Belgium, Brazil, Canada, Colombia +25 more
- Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)Active Not Recruiting
Sponsor: Novartis Pharmaceuticals
Systemic Lupus Erythematosus
United States, Argentina, Australia, Chile, Colombia +10 more
Sponsor: Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension
United States, Argentina, Australia, Belgium, Brazil +22 more
- A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory NeuroblastomaActive Not Recruiting
Sponsor: Eli Lilly and Company
Neuroblastoma
United States, Australia, Belgium, France, Germany +4 more
Sponsor: Boehringer Ingelheim
Heart Failure
United States, Argentina, Australia, Belgium, Brazil +25 more
Sponsor: Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
United States, Argentina, Australia, Austria, Belgium +24 more
- A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)Recruiting
Sponsor: Merck Sharp & Dohme LLC
Ovarian Neoplasms · Ovarian Cancer
United States, Argentina, Australia, Austria, Belgium +24 more
Sponsor: Royal Marsden NHS Foundation Trust
Locally Advanced Gastric Adenocarcinoma · MSI-H/dMMR Gastric Cancer · MSI-H/dMMR Gastroesophageal-junction Cancer
United Kingdom
Sponsor: Eli Lilly and Company
Carcinoma, Transitional Cell · Urinary Bladder Neoplasms · Neoplasm Metastasis
United States, Australia, Brazil, Canada, China +14 more
- Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 AlterationsActive Not Recruiting
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Uterine Neoplasms · Uterine Cervical Neoplasms · Biliary Tract Neoplasms · Urologic Neoplasms
United States, Belgium, Germany, Italy, Japan +3 more
Sponsor: Merck Sharp & Dohme LLC
Non Small Cell Lung Cancer
United States, Argentina, Australia, Austria, Belgium +26 more
Sponsor: Tessera Therapeutics, Inc.
Alpha-1 Antitrypsin Deficiency (AATD)
United States, Australia, United Kingdom
- A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative ColitisRecruiting
Sponsor: AbbVie
Ulcerative Colitis
United States, Belgium, Brazil, Canada, China +10 more
Sponsor: Amgen
Metastatic Colorectal Cancer
United States, Argentina, Australia, Austria, Belgium +30 more
- RTX001 Autologous Engineered Macrophages for Liver CirrhosisActive Not Recruiting
Sponsor: Resolution Therapeutics Limited
End-stage Liver Disease (ESLD) · Cirrhosis, Liver · Cirrhosis, Decompensated · Liver Diseases
Spain, United Kingdom
- A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)Active Not Recruiting
Sponsor: Merck Sharp & Dohme LLC
Chronic Lymphocytic Leukemia · Mantle Cell Lymphoma · Follicular Lymphoma · Richter Transformation Lymphoma
United States, Brazil, Canada, Chile, China +16 more
Sponsor: Merck Sharp & Dohme LLC
Heterozygous Familial Hypercholesterolemia (HeFH)
United States, Australia, Belgium, Brazil, Chile +11 more